|
1
|
Armah HB and Parwani AV: Xp11.2
translocation renal cell carcinoma. Arch Pathol Lab Med.
134:124–129. 2010.PubMed/NCBI
|
|
2
|
Komai Y, Fujiwara M, Fujii Y, Mukai H,
Yonese J, Kawakami S, Yamamoto S, Migita T, Ishikawa Y, Kurata M,
et al: Adult Xp11 translocation renal cell carcinoma diagnosed by
cytogenetics and immunohistochemistry. Clin Cancer Res.
15:1170–1176. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Argani P, Olgac S, Tickoo SK, Goldfischer
M, Moch H, Chan DY, Eble JN, Bonsib SM, Jimeno M, Lloreta J, et al:
Xp11 translocation renal cell carcinoma in adults: Expanded
clinical, pathologic, and genetic spectrum. Am J Surg Pathol.
31:1149–1160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rais-Bahrami S, Drabick JJ, De Marzo AM,
Hicks J, Ho C, Caroe AE and Argani P: Xp11 translocation renal cell
carcinoma: Delayed but massive and lethal metastases of a
chemotherapy-associated secondary malignancy. Urology.
70:178.e3–178.e6. 2007. View Article : Google Scholar
|
|
5
|
Armah HB and Parwani AV: Renal cell
carcinoma in a 33-year-old male with an unusual morphology and an
aggressive clinical course: Possible Xp11.2 translocation.
Pathology. 40:306–308. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsuda M, Davis IJ, Argani P, Shukla N,
McGill GG, Nagai M, Saito T, Laé M, Fisher DE and Ladanyi M: TFE3
fusions activate MET signaling by transcriptional up-regulation,
defining another class of tumors as candidates for therapeutic MET
inhibition. Cancer Res. 67:919–929. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Camparo P, Vasiliu V, Molinie V, Couturier
J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R,
et al: Renal translocation carcinomas: Clinicopathologic,
immunohistochemical, and gene expression profiling analysis of 31
cases with a review of the literature. Am J Surg Pathol.
32:656–670. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choueiri TK, Lim ZD, Hirsch MS, Tamboli P,
Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng
DY, et al: Vascular endothelial growth factor-targeted therapy for
the treatment of adult metastatic Xp11.2 translocation renal cell
carcinoma. Cancer. 116:5219–5225. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Malouf GG, Camparo P, Oudard S,
Schleiermacher G, Theodore C, Rustine A, Dutcher J, Billemont B,
Rixe O, Bompas E, et al: Targeted agents in metastatic Xp11
translocation/TFE3 gene fusion renal cell carcinoma (RCC): A report
from the Juvenile RCC Network. Ann Oncol. 21:1834–1838. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sudour-Bonnange H, Leroy X, Chauvet MP,
Classe M, Robin PM and Leblond P: Cutaneous metastases during an
aggressive course of Xp11.2 translocation renal cell carcinoma in a
teenager. Pediatr Blood Cancer. 61:1698–1700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Flanigan RC, Salmon SE, Blumenstein BA,
Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N and Crawford
ED: Nephrectomy followed by interferon alfa-2b compared with
interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J
Med. 345:1655–1659. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mickisch GH, Garin A, van Poppel H, de
Prijck L and Sylvester R: European Organisation for Research and
Treatment of Cancer (EORTC) Genitourinary Group: Radical
nephrectomy plus interferon-alfa-based immunotherapy compared with
interferon alfa alone in metastatic renal-cell carcinoma: A
randomised trial. Lancet. 358:966–970. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choueiri TK, Xie W, Kollmannsberger C,
North S, Knox JJ, Lampard JG, McDermott DF, Rini BI and Heng DY:
The impact of cytoreductive nephrectomy on survival of patients
with metastatic renal cell carcinoma receiving vascular endothelial
growth factor targeted therapy. J Urol. 185:60–66. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Conti SL, Thomas IC, Hagedorn JC, Chung
BI, Chertow GM, Wagner TH, Brooks JD, Srinivas S and Leppert JT:
Utilization of cytoreductive nephrectomy and patient survival in
the targeted therapy era. Int J Cancer. 134:2245–2252. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heng DY, Xie W, Regan MM, Warren MA,
Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al:
Prognostic factors for overall survival in patients with metastatic
renal cell carcinoma treated with vascular endothelial growth
factor-targeted agents: Results from a large, multicenter study. J
Clin Oncol. 27:5794–5799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heng DY, Wells JC, Rini BI, Beuselinck B,
Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T,
et al: Cytoreductive nephrectomy in patients with synchronous
metastases from renal cell carcinoma: Results from the
International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol. 66:704–710. 2014. View Article : Google Scholar : PubMed/NCBI
|
